Bayer considering sale of its diabetes device business
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
BAYER AG is exploring the sale of its diabetes device business as the German company focuses on faster-growing medicines, according to people with knowledge of the matter.
Leverkusen, Germany-based Bayer is working with Credit Suisse Group AG on the potential sale, three of the people said, asking not to be identified because the process is private.
Share with us your feedback on BT's products and services
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
